{"url_path":"/sec/spro/8-k/2026-07-14/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-14","source_url":"https://www.sec.gov/Archives/edgar/data/1701108/0001193125-26-302473-index.html","accession_number":"0001193125-26-302473","cik":"0001701108","ticker":"SPRO","issuer_name":"Spero Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1701108/0001193125-26-302473-index.html","primary_entity_key":"0001701108","primary_entity_name":"Spero Therapeutics, Inc."},"word_count":113,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n \n\nExhibit\nNo.\n  \nDescription\n\n99.1\n  \n[Joint press release issued by Spero Therapeutics, Inc. and Innovent on July 14, 2026](d320658dex991.htm)\n\n99.2\n  \n[Press release issued by Spero Therapeutics, Inc. on July 14, 2026](d320658dex992.htm)\n\n99.3\n  \n[Spero Therapeutics, Inc. Corporate Presentation, dated July 2026](d320658dex993.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document and incorporated as Exhibit 101)\n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nDate: July 14, 2026\n \nSPERO THERAPEUTICS, INC.\n\n \n\n \nBy:\n \n\n/s/ Esther Rajavelu\n\n \n\n \n\n \nEsther Rajavelu\n\n \n\n \n\n \nChief Executive Officer and Chief Financial Officer"}